Overview:
Moderna, a biopharmaceutical company focused on mRNA medicines, partnered with OpenAI to deploy its enterprise-grade generative-AI platform (ChatGPT Enterprise) across the entire organization. The goal was to embed AI broadly — not just in R&D, but in legal, manufacturing, commercial, corporate brand, and other business functions — to transform how work is done, increase human capacity, and accelerate the development of future mRNA products (including vaccines and individualized therapies).
By democratizing AI access internally, Moderna aimed to streamline decision-making, accelerate workflows, and enable a lean organization to operate with the effectiveness of a much larger one — important given its ambition to bring up to 15 new products to market over the next five years.
Key Features:
Deploys enterprise-grade generative AI organization-wide — provided ChatGPT Enterprise to thousands of employees across all business functions to use as AI assistants.
Enables custom AI assistants (“GPTs”) — employees built purpose-specific GPTs for tasks such as dose selection support, contract summarization, internal policy guidance, investor communications, and more.
Automates and augments data-intensive analyses — for example, a “Dose ID” GPT analyzes large clinical datasets, applies dose-selection criteria, generates rationales, and visualizes results to support clinical teams’ decisions.
Streamlines legal, compliance, and administrative workflows — custom GPTs quickly summarize contracts, answer policy questions, and reduce time spent on routine document review.
Supports corporate communications and branding tasks — generates investor-oriented slides, tailors technical messaging for different audiences (e.g., regulators vs general public), helping non-scientific teams communicate effectively.
Results & Impact:
Rapid scale of adoption — 750+ GPTs deployed within two months of rolling out ChatGPT Enterprise.
High user engagement and productivity — about 40% of weekly active users created their own GPTs; average user had ~120 ChatGPT Enterprise conversations per week.
Full penetration in key functions — for instance, the legal team reached 100% adoption of ChatGPT Enterprise in a short period.
Augmented clinical trial workflows — GPT-assisted dose-selection analysis enables the team to process large datasets and generate data-driven dose recommendations, potentially accelerating trial timelines and improving decision quality.
Improved resource efficiency — according to leadership, AI allows a “team of a few thousand” to perform like a much larger organization, supporting Moderna’s goal of scaling output without proportionally scaling headcount.
AI Technology:
AI Model Types: Large Language Models / Generative AI (via ChatGPT Enterprise)
AI Purpose: Automate and augment tasks such as data analysis, document summarization, knowledge retrieval, content generation, and decision support
Application Type: Operations, Clinical Development, Legal & Compliance, Corporate Communications, R&D support
Target Users:
Clinical development teams / researchers
Legal and compliance teams
Business operations and manufacturing staff
Corporate brand and communications teams
Executive leadership and decision-makers